- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01887821
Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
This is a study of drug effectiveness for 2 treatments of vivax malaria, which is one of the two main types of malaria in Viet Nam. There are two important drugs used in Viet Nam for treating vivax malaria, Chloroquine and Artemisinin. Sometimes, when medicines are used for many years they become less effective at treating a disease, especially when they are not used at adequate doses according to national guidelines or when counterfeit drugs are available in the market. The purpose of this study is to check that Chloroquine and Artemisinin, are still effective for patients in Viet Nam.
Participants in this study will be treated with either Dihydroartemisinin-Piperaquine (DHA-PPQ) or Chloroquine (CQ) for 3 days. Both drugs are recommended by the national guidelines to treat vivax malaria. The investigators would like to know if both of these treatments are equally effective so half of the patients in the study will be treated with DHA-PPQ and the other half will be treated with CQ. This way the investigators can compare the drugs to find out if one is better than the other.
Participants will be followed for 3 days in hospital, then regularly by follow-up visits until the 63rd day. Tests will be done to determine the amount of drug and malaria parasites in the participant's body and how the blood cells react to the malaria. The parasite will be tested to determine what type it is and how it reacts to the treatment.
The results of the study will be used to inform malaria treatment guidelines in Viet Nam.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Binh Phuoc
-
Bu Gia Map, Binh Phuoc, Vietnam
- Bu Gia Map Health Station
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 3 years;
- Mono-infection with P. vivax, parasitemia > 250/µl asexual forms for in vivo and >8000 asexual parasites/µl blood for in vitro testing;
- Presence of axillary or tympanic temperature ≥ 37.5 °C or history of fever during the past 24 h;
- Ability to swallow oral medication;
- Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- Informed consent/assent
Exclusion Criteria:
- Presence of general danger signs or severe malaria according to the definitions of WHO (2000);
- Mixed infection with P.falciparum and P.vivax of other plasmodium species;
- Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- Regular medication, which may interfere with antimalarial pharmacokinetics;
- Received antimalarial drugs in the previous 48 hours;
- History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- Splenectomy;
- First trimester of pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Chloroquine
25mg base/kg for 3 days
|
|
Active Comparator: Dihydroartemisinin/Piperaquine
Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with adequate response to treatment
Time Frame: Day 63
|
Adequate response = adequate clinical and parasitological response.
Absence of parasitaemia on day 63, irrespective of temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.
|
Day 63
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients classified as Early Treatment Failures
Time Frame: Day 63
|
One or more of the following:
|
Day 63
|
The parasite clearance time
Time Frame: Assessed every 6 hours until Day 3, or two consecutive parasite negative slides.
|
Defined as the time in hours from the first treatment dose to the first of two consecutive parasitemia counts of zero.
|
Assessed every 6 hours until Day 3, or two consecutive parasite negative slides.
|
Fever clearance time
Time Frame: Assessed every 6 hours until Day 3, or 24 hours without fever
|
Defined as the time in hours from the first treatment dose to the start of the first sustained period of 24 hours without fever
|
Assessed every 6 hours until Day 3, or 24 hours without fever
|
Frequency of adverse and serious adverse events
Time Frame: Day 63
|
Day 63
|
|
Proportion of patients classified as Late Clinical Failures
Time Frame: Day 63
|
One or more of the following:
|
Day 63
|
Proportion of patients classified as Late Parasitological Failures
Time Frame: Day 63
|
Presence of parasitaemia on any day between day 7 and day 63 with temperature < 37.5 ºC in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure
|
Day 63
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07MA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasmodium Vivax Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedPlasmodium Falciparum | Plasmodium Vivax MalariaUnited States
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaThailand
-
University of OxfordMahidol UniversityRecruiting
-
Centers for Disease Control and PreventionTerminated
-
U.S. Army Medical Research and Development CommandUnited States Department of Defense; Walter Reed Army Institute of Research...CompletedPlasmodium Vivax MalariaUnited States
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
Clinical Trials on Chloroquine
-
Dinka DugassaEthiopian Public Health InstituteCompletedMalaria | Efficacy | Vivax Malaria | ChloroquineEthiopia
-
GlaxoSmithKlineMedicines for Malaria VentureCompletedMalaria, VivaxThailand, India, Brazil, Ethiopia, Peru, Bangladesh, Cambodia, Philippines
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedCOVID-19 | SARS-CoV Infection | Clinical Trial | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil
-
Ministry of Health, BhutanMenzies School of Health Research; Asia Pacific Malaria Elimination NetworkUnknown
-
HaEmek Medical Center, IsraelT MAY BIOPHARMA LTD.Terminated
-
Tanta UniversityCompleted
-
Bandim Health ProjectCompleted
-
Maastricht Radiation OncologyNational Cancer Institute (NCI); Maastricht University Medical CenterTerminatedSmall Cell Lung CancerNetherlands
-
Bandim Health ProjectCompleted
-
PATHMahidol Oxford Tropical Medicine Research UnitTerminated